Efficacy, Safety, and Confirmation of the Recommended Phase 2 Starting Dose of the Combination of Ruxolitinib (RUX) and Panobinostat (PAN) in Patients (Pts) with Myelofibrosis (MF)Claire Harrison, Vincent Ribrag, Francesco Passamonti et al.|Blood|2015Cited by 39
Efficacy, Safety, and Confirmation of the Recommended Phase 2 Dose of Ruxolitinib Plus Panobinostat in Patients with Intermediate or High-Risk MyelofibrosisJean‐Jacques Kiladjian, Claire Harrison, Florian H. Heidel et al.|Blood|2014Cited by 14